0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Neurology |

This Month in Archives of Neurology FREE

Arch Neurol. 2008;65(11):1415-1416. doi:10.1001/archneur.65.11.1415.
Text Size: A A A
Published online

MEDULLOBLASTOMA 2008

Packer and VezinaArticle cite medulloblastoma as the most common malignant childhood brain tumor. Children have a high likelihood of long-term survival, as 80% or more will be alive 5 years after diagnosis and treatment, with many being cured of the disease. In their comprehensive review, the authors point out that molecular targeted therapies are being studied in patients and hold great promise.

TISSUE PLASMINOGEN ACTIVATOR, ISCHEMIC STROKE, AND POTENTIAL LEGAL ISSUES

Liang and colleaguesArticle point out that the use of tissue plasminogen activator (tPA) is efficacious and can result in highly improved outcomes for most eligible patients. However, they state that these findings may implicate important potential legal issues. Informed consent concerns and, potentially, medical malpractice claims may result, particularly in the contexts of evidence-based practice, pay for performance, and the currently limited use of tPA for eligible patients.

INTERFERON BETA–INDUCED RESTORATION OF REGULATORY T-CELL FUNCTION IN MULTIPLE SCLEROSIS

Korporal et alArticle evaluated the effect of interferon beta (IFN-β) on the suppressive activity and homeostasis of circulating regulatory T (Treg) cells in patients with multiple sclerosis. They find that the increase in Treg-cell inhibitory capacities mediated by IFN-β can be explained by its effect on the homeostatic balance within the Treg compartment. Editorial perspective is provided by Harald H. Hofstetter, MD, Olaf Stuve, MD, PhD, and Hans-Peter Hartung, MD.Article

TREATMENT OF NEUROMYELITIS OPTICA WITH RITUXIMAB

Jacob and colleaguesArticle evaluated the use and efficacy of rituximab for neuromyelitis optica (NMO). They present clear evidence that, in NMO, treatment with rituximab appears to result in reduced attack frequency with subsequent stabilization or improvement in disability.

Place holder to copy figure label and caption

Relapses in patients with neuromyelitis optica before and after treatment with rituximab. The vertical lines indicate start of new treatments; horizontal line, patient.

Graphic Jump Location

MAGNETIC RESONANCE DISEASE SEVERITY SCALE PREDICTS PROGRESSION IN MULTIPLE SCLEROSIS

Bakshi et alArticle have combined brain magnetic resonance imaging (MRI) lesion and atrophy measures to show that these measures can predict clinical progression in patients with multiple sclerosis and provide the basis to develop an MRI-based continuous scale as a marker of multiple sclerosis severity.

GRAY MATTER MAGNETIZATION TRANSFER IMAGING: A MARKER OF PROGRESSION IN MULTIPLE SCLEROSIS

Khaleeli and colleaguesArticle provide convincing data that gray matter magnetization transfer ratio, normalized magnetization transfer ratio, meets many of the criteria for a surrogate marker of progression in early primary progressive multiple sclerosis.

PULSED ORAL STEROIDS FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

Muley et alArticle show that pulsed oral methylprednisone is efficacious in the long-term treatment of chronic idiopathic demyelinating polyneuropathy and is relatively well tolerated.

ALZHEIMER AND COGNITIVE RESERVE: EDUCATION EFFECT VARIES WITH CARBON 11–LABELED PITTSBURGH COMPOUND B UPTAKE

Roe and colleaguesArticle provide data supporting the view that cognitive reserve influences the association between Alzheimer disease pathology and cognition.

THE TAU GENE REGION CHROMOSOME INVERSION IN PROGRESSIVE SUPRANUCLEAR PALSY, CORTICOBASAL DEGENERATION, AND RELATED DISORDERS

Webb et alArticle performed a genome-wide association scan to search for variants that confer susceptibility to 4 tauopathies and clinically related disorders. This article focuses on the results from an inverted region of chromosome 17 that contains the MAPT gene. They conclude that the association found in the tauopathies across this interval further supports the theory that 1 or more susceptibility loci in this region is affecting susceptibility specifically to progressive supranuclear palsy and corticobasal degeneration.

TDP-43 IN THE CEREBROSPINAL FLUID OF PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION AND AMYOTROPHIC LATERAL SCLEROSIS

Steinacker and colleaguesArticle find that patients with frontotemporal lobar degeneration (FTLD) and amyotropic lateral sclerosis (ALS) had higher transactivation response DNA-binding protein 43 (TDP-43) levels compared with control subjects, but with an overlap of values. Future determination of TDP-43 in the cerebrospinal fluid might aid in characterizing subgroups of patients across the ALS/FTLD disease spectrum.

SEVEN-TESLA PROTON MAGNETIC RESONANCE IMAGING IN X-LINKED ADRENOLEUKODYSTROPHY

Ratai et alArticle report that 7-Tesla proton magnetic resonance spectroscopic imaging shows differences in the neurochemistry of patients with adult cerebral adrenoleukodystrophy but is unable to distinguish adrenomyeloneuropathy from female heterozygotes. Myo-inositol/creatine correlates with the severity of symptoms and may be a meaningful biomarker in adult X-linked adrenoleukodystrophy.

A NOVEL DUPLICATION OF 5Q23.2 IN AUTOSOMAL DOMINANT LEUKODYSTROPHY

Meijer and colleaguesArticle identified a novel duplication on chromosomal band 5q23.2 in a French Canadian family with autosomal dominant leukodystrophy, supporting duplication of LMNB1 as the disease-causing mutation.

YOUNG-ONSET DEMENTIA

Kelley et alArticle find that young-onset dementia (onset prior to 45 years of age) encompasses a broad variety of etiologies, with a sizable minority having a potentially treatable disorder.

AMYLOID DEPOSITION IS FREQUENT AND OFTEN IS NOT ASSOCIATED WITH SIGNIFICANT COGNITIVE IMPAIRMENT IN THE ELDERLY

Aizenstein et alArticle show that amyloid deposition can be identified in cognitively unimpaired elderly persons during life and the prevalence of asymptomatic amyloid deposition may be similar to that of symptomatic amyloid deposition. They find that one can remain cognitively unimpaired in the presence of significant amyloid burden.

ANALYSES OF THE NATIONAL INSTITUTE ON AGING LATE-ONSET ALZHEIMER DISEASE FAMILY STUDY IMPLICATE ADDITIONAL LOCI

Lee et alArticle conducted a linkage analysis and family-based and case-control association analyses as part of the National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease (NIA-LOAD). They report that there are potentially several additional loci that may harbor genetic variants associated with LOAD. This data set provides a wealth of phenotypic and genotypic information for use as a resource in discovery and confirmatory research.

Figures

Place holder to copy figure label and caption

Relapses in patients with neuromyelitis optica before and after treatment with rituximab. The vertical lines indicate start of new treatments; horizontal line, patient.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

225 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs